ARCT-032

BIOLOGICAL2 trials

Sponsors

Arcturus Therapeutics, Inc.

Conditions

CFTR Gene MutationCystic Fibrosis

Phase 1

Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects and Adults With Cystic Fibrosis.

CompletedNCT05712538

Arcturus Therapeutics, Inc.Cystic Fibrosis

Start: 2023-02-15End: 2024-07-29Updated: 2024-11-13

Phase 2

Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis

RecruitingNCT06747858

Arcturus Therapeutics, Inc.CFTR Gene Mutation, Cystic Fibrosis

Start: 2024-12-12End: 2027-06-01Target: 33Updated: 2026-05-08